Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Resveratrol Exerts Differential Effects in Vitro and in Vivo against Ovarian Cancer Cells

  • Stakleff, Kimberly Sloan (Kenneth Calhoun Research Laboratory, Akron General Medical Center) ;
  • Sloan, Tricia (Kenneth Calhoun Research Laboratory, Akron General Medical Center) ;
  • Blanco, Denise (Kenneth Calhoun Research Laboratory, Akron General Medical Center) ;
  • Marcanthony, Sharon (Department of Obstetrics and Gynecology, Akron General Medical Center) ;
  • Booth, Tristan D. (Clinical and Innovative Development, Pharmascience, Inc.) ;
  • Bishayee, Anupam (Department of Pharmaceutical and Administrative Sciences, School of Pharmacy, American University of Health Sciences)
  • Published : 2012.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Epithelial ovarian cancer represents the most lethal gynecological cancer, and the high mortality rate makes this malignancy a major health concern. Poor prognosis results from an inability to detect ovarian cancers at an early, curable stage, as well as from the lack of an effective therapy. Thus, effective and novel strategies for prevention and treatment with non-toxic agents merit serious consideration. Resveratrol, obtained from grapes, berries, peanuts and red wine, has been shown to have a potent growth-inhibitory effect against various human cancer cells as well as in in vivo preclinical cancer models. The objective here was to evaluate potential antitumor effects of resveratrol in both in vitro and in vivo NuTu-19 ovarian cancer models. In vitro an invasion assay was performed. After 48 h, the numbers of viable cells that invaded the extracellular matrix layer were reduced by 94% with resveratrol in comparison to control. For the in vivo anti-tumor assessment, 10 rats were injected with NuTu-19 cells into the ovarian bursa. Thereafter, half were provided with a diet mixed with a dose of 100 mg resveratrol/kg body weight/day for 28 days. Following sacrifice, anticancer effects were assessed by histological evaluation of ovarian as well as surrounding tissues, and immunohistochemical detection of cell proliferation and apoptosis, but there were no observable differences between the control and resveratrol-treated groups for any of the biological endpoints. While resveratrol is effective in suppressing the in vitro cellular invasion of NuTu-19 ovarian cancer cells, these effects do not appear to impact on in vivo NuTu-19 ovarian cancers in rats.

Keywords

References

  1. Aalto ML, Collan Y (1986). Periodic acid-Schiff stain as a prognostic indicator in serous and mucinous ovarian tumors. Int J Gynaecol Obstet, 24, 27-34. https://doi.org/10.1016/0020-7292(86)90020-2
  2. Aggarwal BB, Bhardwaj A, Aggarwal RS, et al (2004). Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res, 24, 2783-40.
  3. Athar M, Back JH, Kopelovich L, Bickers DR, Kim Al (2009). Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch Biochem Biophys, 486, 95-102. https://doi.org/10.1016/j.abb.2009.01.018
  4. Banerjee S, Bueso Ramos C, Aggarwal BB (2002). Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor- ${\kappa}B$, cycloxygenase 2, and matrix metalloprotease 9. Cancer Res, 62, 4945-54.
  5. Becher OJ, Holland EC (2006). Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res, 66, 3355-9. https://doi.org/10.1158/0008-5472.CAN-05-3827
  6. Bishayee A (2009). Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res, 2, 409-18. https://doi.org/10.1158/1940-6207.CAPR-08-0160
  7. Bishayee A, Dhir N (2009). Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem-Biol Interact, 179, 131-44. https://doi.org/10.1016/j.cbi.2008.11.015
  8. Bishayee A (2012). Current advances in cancer prevention and treatment by natural products. Curr Pharm Biotechnol, 13, 115-6. https://doi.org/10.2174/138920112798868629
  9. Bjorklund M, Roos J, Gogvadze V, Shoshan M (2011). Resveratrol induces SIRT1- and energy-stress-independent inhibition of tumor cell regrowth after low dose-dose platinum treatment. Cancer Chemother Pharmacol, 68, 1459-67. https://doi.org/10.1007/s00280-011-1640-x
  10. Bove K, Lincoln DW, Tsan MF (2001). Effect of resveratrol on growth of 4T1 breast cancer cells in vitro and in vivo. Biochem Biophys Res Commun, 291, 1001-5.
  11. Brard L, Granai CO, Swamy N (2006). Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma. Gynecol Oncol, 100, 116-27. https://doi.org/10.1016/j.ygyno.2005.07.129
  12. Brewer MA, Johnson K, Follen M, Gershenson D, Bast R, Jr (2003). Prevention of ovarian cancer: intraepithelial neoplasia. Clin Cancer Res, 9, 20-30.
  13. Cao Z, Fang J, Xia C, Shi X, Jiang BH (2004). trans-3,4,5'- Trihydroxystibene inhibits hypoxia-inducible factor 1$\alpha$ and vascular endothelial growth factor expression in human ovarian cancer cells. Clin Cancer Res, 10, 5253-63. https://doi.org/10.1158/1078-0432.CCR-03-0588
  14. Crowell JA, Korytko PJ, Morrissey Rl, Booth TD, Levine BS (2004). Resveratrol-associated renal toxicity. Toxicol Sci, 82, 614-9. https://doi.org/10.1093/toxsci/kfh263
  15. Delmas D, Solary E, Latruffe N (2011). Resveratrol, a phytochemical inducer of multiple cell death pathways: apoptosis, autophagy and mitotic catastrophe. Curr Med Chem, 18, 1100-21. https://doi.org/10.2174/092986711795029708
  16. Dennis T, Fanous M, Mousa S (2009). Natural products for chemopreventive and adjunctive therapy in oncologic disease. Nutr Cancer, 61, 587-97. https://doi.org/10.1080/01635580902825530
  17. Feki A, Jefford CE, Berardi P, et al (2005). BARD1 induces apoptosis by catalyzing phosphorylation of p53 by DNAdamage response kinase. Oncogene, 24, 3726-37. https://doi.org/10.1038/sj.onc.1208491
  18. Fremont L (2000). Biological effects of resveratrol. Life Sci, 66, 663-73. https://doi.org/10.1016/S0024-3205(99)00410-5
  19. Gescher AJ, Steward WP (2003). Relationship between mechanisms, bioavailability, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol Biomarkers Prev, 12, 953-7.
  20. Gullett NP, Ruhul Amin AR, Bayraktar S, et al. (2010) Cancer prevention with natural compounds. Semin Oncol, 37, 258-81. https://doi.org/10.1053/j.seminoncol.2010.06.014
  21. Guo L, Peng Y, Yao J, (2010). Anticancer activity and molecular mechanism of resveratrol-bovine serum albumin nanoparticles on subcutaneously implanted human primary ovarian carcinoma cells in nude mice. Cancer Biother Radiopharm, 25, 471-7. https://doi.org/10.1089/cbr.2009.0724
  22. Harikumar KB, kunnumakkara AB, Sethi G, et al. (2010) Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer, 127, 257-68.
  23. Harper CE, patel BB, Wang J, et al (2007). Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis, 28, 1946-53. https://doi.org/10.1093/carcin/bgm144
  24. Hebbar V, Shen G, Hu R, et al. (2005) Toxicogenomics of resveratrol in rat liver. Life Sci, 76, 2299-314. https://doi.org/10.1016/j.lfs.2004.10.039
  25. Hoekstra A, Rodriguez GC (2009). Chemoprevention of ovarian cancer. Cancer Treat Res, 149, 3-34. https://doi.org/10.1007/978-0-387-98094-2_1
  26. Hsu SM, Raine L, Fanger H (1981). Use of avidin-biotinperoxidase complex (ABC) in immunoperoxidase techniques: a comparison between (ABC) and unlabeled antibody (PAP) procedures. J Histochem Cytochem, 29, 577-80. https://doi.org/10.1177/29.4.6166661
  27. Jang M, Cai L, Udeani GO, et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275, 218-20. https://doi.org/10.1126/science.275.5297.218
  28. Kueck A, Opipari AW, Griffith KA, et al. (2007) Resveratrol inhibits glucose metabolism in human ovarian cancer cells. Gynecol Oncol, 107, 450-7. https://doi.org/10.1016/j.ygyno.2007.07.065
  29. Kundu JK, Surh YJ (2008). Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett, 269, 243-61. https://doi.org/10.1016/j.canlet.2008.03.057
  30. Lee MH, Choi BY, Kundu JK, et al (2009). Resveratrol suppresses growth of human ovarian cancer cells in culture and in a murine xenograft model: eukaryotic elongation factor 1A2 as a potential target. Cancer Res, 69, 7449-58. https://doi.org/10.1158/0008-5472.CAN-09-1266
  31. Li ZG, Hong T, Shimada Y, et al (2002). Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis, 23, 1531-6. https://doi.org/10.1093/carcin/23.9.1531
  32. Lin C, Crawford DR, Lin S, et al. (2011) Inducible COX- 2 dependent apoptosis in human ovarian cancer cells. Carcinogenesis, 32, 19-26. https://doi.org/10.1093/carcin/bgq212
  33. Marimuthu P, Kaur K, Kandalam U, et al. (2011). Treatment of ovarian cancer cells with nutlin-3 and resveratrol combination leads to apoptosis via caspase activation. J Med Food, 14, 46-52. https://doi.org/10.1089/jmf.2009.0270
  34. Medvetz DA, Stakleff KD, Schreiber T, et al. (2007) Ovarian cancer activity of cyclic amine and thiaether metal complexes. J Med Chem, 50, 1703-6. https://doi.org/10.1021/jm060857s
  35. Mills GB (2002). Mechanisms underlying chemoprevention of ovarian cancer. Clin Cancer Res, 8, 7-10.
  36. NIH Consensus Development Panel on Ovarian Cancer (1995). Ovarian cancer: screening, treatment and follow-up. J Am Med Assoc, 273, 491-7. https://doi.org/10.1001/jama.1995.03520300065039
  37. Niles RM, Cook CP, Meadows GG, et al. (2006). Resveratrol is rapidly metabolized in athymic (nu/nu) mice and does not inhibit human melanoma xenograft tumor growth. J Nutr, 136, 2542-6.
  38. Niles RM, Mcfarland M, Weimer MB, et al. (2003) Resveratrol is a potent inducer of apoptosis in human melanoma cells. Cancer Lett, 190, 157-63. https://doi.org/10.1016/S0304-3835(02)00676-6
  39. Opipari JR, AW, Tan L, et al (2004). Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res, 64, 696-703. https://doi.org/10.1158/0008-5472.CAN-03-2404
  40. Park SY, Jeong KJ, Lee J, et al. (2007) Hypoxia enhances, LPAinduced HIF-$1{\alpha}$ and VEGF expression: their inhibition by resveratrol. Cancer Lett, 258, 63-9. https://doi.org/10.1016/j.canlet.2007.08.011
  41. Raj MHG, Abd Elmageed ZY, Zhou J, et al (2008). Synergistic action of dietary phyto-antioxidants on survival and proliferation of ovarian cancer cells. Gynecol Oncol, 110, 432-8. https://doi.org/10.1016/j.ygyno.2008.05.001
  42. Rezk YA, Balulad SS, Keller RS, Bennett JA (2006). Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic can cell lines and in rodent heart. Am J Obstet Gynecol, 194, 23-6. https://doi.org/10.1016/j.ajog.2005.11.030
  43. Rose GS, Toco LM, Granger GA, et al (1996) Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. Am J Obstet Gynecol, 175, 593-9. https://doi.org/10.1053/ob.1996.v175.a73595
  44. Sankaranarayanan R, Ferlay J (2006). Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol, 20, 207-25. https://doi.org/10.1016/j.bpobgyn.2005.10.007
  45. Schneider Y, Duranton B, Gosse F, et al (2001) Resveratrol inhibits intestinal tumorigenesis and modulates host-defenserelated gene expression in an animal model of human familial adenomatous polyposis. Nutr Cancer, 39, 102-7. https://doi.org/10.1207/S15327914nc391_14
  46. Schumacher JJ, Dings RPM, Costin J, et al (2007). Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells. Cancer Res, 67, 3683-90. https://doi.org/10.1158/0008-5472.CAN-06-3608
  47. Sengottuvelan M, Viswanathan P, Nalini N (2006). Chemopreventive effect of trans-resveratrol - a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine induced colon carcinogenesis. Carcinogenesis, 27, 1038-46. https://doi.org/10.1093/carcin/bgi286
  48. Shukla Y, Singh R (2011). Resveratrol and cellular mechanisms of cancer prevention. Ann NY Acad Sci, 1215, 1-8. https://doi.org/10.1111/j.1749-6632.2010.05870.x
  49. Siegel R, Naishadham, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138
  50. Sloan Stakleff KD, Rouse AG, Ryan AP, Haller NA, Von Gruenigen VE (2005). A novel early-stage orthotopic model for ovarian cancer in the Fischer 344 rat. Int J Gynecol Cancer, 15, 246-54. https://doi.org/10.1111/j.1525-1438.2005.15211.x
  51. Sloan Stakleff KD, Von Gruenigen VE (2003). Rodent models for ovarian cancer research. Int J Gynecol Cancer, 13, 405-12. https://doi.org/10.1046/j.1525-1438.2003.13317.x
  52. Smith ER, Daly MB, Xu XX (2004). A mechanism for cox-2 inhibitor anti-inflammatory activity in chemoprevention of epithelial cancers. Cancer Epidem Biomarkers Prev, 13, 144-5. https://doi.org/10.1158/1055-9965.EPI-461-2
  53. Stan SD, Kar S, Stoner GD, Singh SV (2008). Bioactive food components and cancer risk reduction. J Cell Biochem, 104, 339-56. https://doi.org/10.1002/jcb.21623
  54. Subbaramaiah K, Zakim D, Weksler BB, Dannenberg AJ (1997). Inhibition of cyclooxygenase: a novel approach to cancer prevention. Proc Soc Exp Biol Med, 216, 201-10. https://doi.org/10.3181/00379727-216-44170
  55. Subramanian L, Youssef S, Bhattacharya S, et al. (2010) Resveratrol: challenges in translation to the clinic - a critical discussion. Clin Cancer Res, 16, 5942-8. https://doi.org/10.1158/1078-0432.CCR-10-1486
  56. Teicher BA (2006). Tumor models for efficacy determination. Mol Cancer Ther, 5, 2435-43. https://doi.org/10.1158/1535-7163.MCT-06-0391
  57. Tessitore L, Davit A, Sarotto I, Caderni G (2000). Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21 (CIP) expression. Carcinogenesis, 21, 1619-22. https://doi.org/10.1093/carcin/21.8.1619
  58. Tyagi A, Singh RP, Agarwal C, Siriwardana S, Sciafani RA (2005). Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis, 26, 1978-87. https://doi.org/10.1093/carcin/bgi165
  59. Visintin I, Feng A, Longton G, et al (2008). Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res, 14, 1065-72. https://doi.org/10.1158/1078-0432.CCR-07-1569
  60. Weng CJ, Yen GC (2012). Chemopreventive effects of dietary phytochemicals against cancer invasion and metastasis: phenolic acids, monophenol, polyphenol, and their derivatives. Cancer Treat Rev, 38, 76-87. https://doi.org/10.1016/j.ctrv.2011.03.001
  61. Yang SH, Kim JS, Oh TJ, et al (2003) Genome-scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray. Int J Oncol, 22, 741-50.
  62. Zhou H-B, Chen J-J, Wang W-X, Cai J-T, Du Q (2005). Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice. World J Gastroenterol, 11, 280-4. https://doi.org/10.3748/wjg.v11.i2.280

Cited by

  1. Anticarcinogenic, Cardioprotective, and Other Health Benefits of Tomato Compounds Lycopene, α-Tomatine, and Tomatidine in Pure Form and in Fresh and Processed Tomatoes vol.61, pp.40, 2013, https://doi.org/10.1021/jf402654e
  2. Targeting Cancer with Nano-Bullets: Curcumin, EGCG, Resveratrol and Quercetin on Flying Carpets vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.3865
  3. Molecular Approaches Toward Targeted Cancer Prevention with Some Food Plants and Their Products: Inflammatory and Other Signal Pathways vol.66, pp.2, 2014, https://doi.org/10.1080/01635581.2014.864420
  4. Identification of High Affinity Non-Peptidic Small Molecule Inhibitors of MDM2-p53 Interactions through Structure-Based Virtual Screening Strategies vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3759
  5. Antiangiogenic Activity of Mononuclear Copper(II) Polypyridyl Complexes for the Treatment of Cancers vol.58, pp.13, 2015, https://doi.org/10.1021/acs.jmedchem.5b00651
  6. Gene expression profiling of DMU-212-induced apoptosis and anti-angiogenesis in vascular endothelial cells vol.54, pp.4, 2016, https://doi.org/10.3109/13880209.2015.1071414
  7. Efficacy of Bioactive Molecules: An Overview of Potentially Antitumor Phytochemicals and Currently Available Lipid-Based Delivery Systems vol.2017, pp.1687-8469, 2017, https://doi.org/10.1155/2017/7351976
  8. The Role of Resveratrol in Cancer Therapy vol.18, pp.12, 2017, https://doi.org/10.3390/ijms18122589